🔬 Siphtor← Home
EngineSiphtor Multi-Agent Research Pipeline
CoverageGlobal Macro / Trade Telemetry / Corporate Filings
Run Duration3m 01s
StatusLive Autonomous Briefing

Siphtor Research

Samsung C&T Q3 Profit Rises on Construction Strength

Samsung C&T’s third-quarter revenue rose 34.5% year-over-year to ₩34.5 trillion, signaling continued strength in its core construction business and a diversified portfolio now including significant investments in bio-pharmaceuticals. The results, detailed in a recent filing, demonstrate the company's ability to capitalize on a robust project pipeline despite broader macroeconomic headwinds.

By Siphtor Media

Published: 11/18/2026

Samsung C&T Q3 Profit Rises on Construction Strength

Samsung C&T’s third-quarter revenue rose 34.5% year-over-year to ₩34.5 trillion, signaling continued strength in its core construction business and a diversified portfolio now including significant investments in bio-pharmaceuticals. The results, detailed in a recent filing, demonstrate the company's ability to capitalize on a robust project pipeline despite broader macroeconomic headwinds.

The operating profit for the quarter reached ₩2.9 trillion, a decrease from ₩3.3 trillion in the same period last year, reflecting increased investment in future growth areas. Revenue growth was led by the construction segment, accounting for 34.4% of total sales, and the trading segment at 37.8%. These two divisions together dominate Samsung C&T’s revenue stream, indicating a sustained focus on its established strengths. The company has also been actively expanding its bio-pharmaceuticals business, which now constitutes 13.9% of revenue, demonstrating a commitment to diversifying beyond traditional construction and trading.

The filing reveals continued investment in research and development, with ₩420 billion allocated to R&D in the third quarter. This includes ongoing projects in areas like low-carbon concrete technology, modular construction, and advanced semiconductor infrastructure, supporting long-term competitiveness. Samsung C&T is also actively pursuing strategic acquisitions, such as the recent deal to acquire PolyPeptide Group AG, a Swiss peptide CDMO, to further expand its bio-pharmaceutical capabilities. The company also highlighted its investment in Human Genome Sciences, Inc. in the U.S., demonstrating a strategy to build a global footprint in the biotech sector.

Samsung C&T's results reflect a strategic balance between maintaining momentum in its core businesses and pursuing growth opportunities in emerging sectors. While operating profit experienced a year-over-year decline, the substantial revenue increase and continued investment in R&D position the company for sustained long-term growth. The company is navigating a complex global economic landscape with a diversified portfolio and a clear focus on innovation, as evidenced by its ongoing expansion in bio-pharmaceuticals and green technologies.

KRX_SAMSUNG_C_TKRX_SAMSUNG_C_T • Corporate Filing Telemetry
Open & Model This Dataset in Siphtor AI

Enjoyed this article?

Siphtor Media subscribers get unlimited articles, interactive charts, and the full economic data dashboard — starting at $7.99/month.

Free newsletter · No spam · Unsubscribe anytime

Keep Exploring